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Introduction: nab-Paclitaxel (nab-P) is approved, in the United 
States, in combination with carboplatin for the first-line treatment of 
advanced non–small-cell lung cancer, based on a randomized phase 3 
trial of nab-P plus carboplatin (nab-P/C) versus solvent-based pacli-
taxel plus carboplatin (sb-P/C). This trial revealed a higher overall 
response rate (33% versus 25%; p = 0.005) and longer, but not sta-
tistically significant, overall and progression-free survival for nab-
P/C versus sb-P/C. In addition, nab-P/C demonstrated lower rates 
of grade 3 or higher peripheral neuropathy, myalgia, arthralgia, 
and neutropenia but higher rates of anemia and thrombocytopenia. 
This report analyzes patient and physician assessment of symptoms 
within this trial.
Methods: Patients completed the taxane subscale of the Functional 
Assessment of Cancer Therapy questionnaire, which focuses on 
taxane toxicity, including peripheral neuropathy and neurotoxic-
ity. Mean baseline scores and changes from baseline are reported. 
Physicians also graded the severity of neuropathy at each patient visit 
using National Cancer Institute Common Toxicity Criteria.
Results: Patients receiving nab-P/C reported significantly less wors-
ening of peripheral neuropathy (p < 0.001), pain (p < 0.001), and hear-
ing loss (p = 0.002). Patient-reported edema was similar between the 
two treatment arms. In agreement with patient-reported symptoms, 
the results of a per-treatment cycle physician assessment of periph-
eral neuropathy also favored nab-P/C over sb-P/C (p < 0.001).
Conclusion: In this trial of patients receiving first-line treatment for 
advanced non–small-cell lung cancer, nab-P/C was associated with 
statistically and clinically significant reductions in patient-reported 
neuropathy, neuropathic pain in the hands and feet, and hearing loss 
compared with sb-P/C.
Key Words: nab-Paclitaxel, Solvent-based paclitaxel, Functional 
Assessment of Cancer Therapy-Taxane, Non–small-cell lung cancer, 
Peripheral neuropathy.
(J Thorac Oncol. 2014;9: 83–90)
The goals of therapy for advanced non–small-cell lung can-cer (NSCLC) are to prolong survival and manage symp-
toms associated with the disease.1 Because survival times for 
patients with advanced NSCLC are relatively short, symptom 
control is an important consideration.2 Treatment can affect 
a patient’s well-being through both symptom control and 
treatment-related toxicity.3 Therefore, treatments that can help 
limit tumor growth (achieve a tumor response)4 while limiting 
toxicity are of paramount importance in this population.3
Underscoring the value of symptom control to patients, 
an analysis of patient preference with respect to chemotherapy 
for advanced NSCLC found that 68% of those interviewed 
would accept chemotherapy if it would substantially reduce 
symptoms, even in the absence of a survival benefit.5
Worsening symptoms may decrease a patient’s indepen-
dence, rendering him or her more dependent on caregivers, 
including family. A number of reports have revealed that many 
patients with terminal cancer are concerned about becoming 
a burden to loved ones at the end of life.6–8 This phenome-
non, known as self-perceived burden, may be experienced at 
minimal to mild levels by 35% of patients and at moderate to 
extreme levels by another 28% of patients according to one 
study.6 This perception of being a burden to loved ones may 
affect a patient’s preference of treatment.8
Symptom management is an important component of 
care in advanced NSCLC because the majority of patients 
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present with disease-related symptoms.2 Symptom control can 
be achieved with tumor response, but it can also be achieved in 
the absence of an objective response, possibly through tumor 
shrinkage that does not meet the criteria to be considered a par-
tial response.2 The effect of tumor response on disease-related 
symptoms is an area of active research, with some but not all 
studies suggesting a link between tumor response and symp-
toms such as cough, dyspnea, chest pain, and systemic symp-
toms (fever, anorexia, and weight loss).9–11 Therefore, tumor 
shrinkage is an important consideration because it may relate 
to both the goals of treatment and the patient’s well-being.
Platinum-based regimens are recommended therapy 
for advanced NSCLC in patients with good performance sta-
tus (PS).1,12 Different platinum doublets offer similar overall 
response rates (ORRs) and overall survival values; therefore, 
the selection of the proper combination partner should be indi-
vidually tailored by clinicians to their patients.12 Solvent-based 
paclitaxel (sb-paclitaxel) is among the recommended platinum 
combination partners.1,12 However, toxicities such as peripheral 
neuropathy, arthralgia, and myalgia are known taxane-associ-
ated side effects.3,13 nab-Paclitaxel was developed to improve 
the therapeutic index of paclitaxel therapy.14 Compared with 
sb-paclitaxel, nab-paclitaxel reaches a 10-fold higher peak 
concentration of free paclitaxel in patients, delivers 33% more 
drug to tumors in preclinical models, and crosses endothe-
lial cells more efficiently.15,16 Furthermore, nab-paclitaxel has 
shown superior ORR and time to progression/progression-free 
survival and favorable safety versus sb-paclitaxel and docetaxel 
in trials of metastatic breast cancer (MBC).14,17
nab-Paclitaxel, either as monotherapy or in combina-
tion with carboplatin (nab-P/C) has demonstrated promising 
efficacy in NSCLC in a number of clinical trials.18–20 These 
findings were recently confirmed in a phase 3 trial in which 
nab-P/C was compared with sb-paclitaxel plus carboplatin 
(sb-P/C) as first-line treatment for patients with advanced 
NSCLC.21 The dose and schedule of nab-P/C was cho-
sen based on the findings of a phase 2 dose-finding study,20 
whereas the sb-P/C regimen was selected because it represents 
an established standard against which to compare nab-P/C.22,23 
Compared with sb-P/C, nab-P/C produced a significantly 
higher ORR (33% versus 25%, respectively; p = 0.005) and a 
nonsignificant 1-month longer median overall survival versus 
sb-P/C (12.1 versus 11.2 months, respectively; p = 0.271).21 In 
addition, the safety profile revealed lower rates of physician-
assessed grade 3 or higher sensory neuropathy, neutropenia, 
myalgia, and arthralgia for nab-P/C but lower rates of grade 
3 or higher anemia and thrombocytopenia for sb-P/C. On the 
basis of these findings, the U.S. Food and Drug Administration 
approved nab-P/C for locally advanced or metastatic NSCLC 
as first-line treatment in patients who are not candidates for 
curative surgery or radiation therapy.24
The Functional Assessment of Cancer Therapy 
(FACT)-General questionnaire is a reliable and validated 
tool to measure symptoms and quality of life (QoL) from 
the perspective of a patient with cancer.25 The tool consists 
of subscales that measure physical well-being, social/family 
well-being, emotional well-being, functional well-being, and 
patient perception of his or her relationship with the physi-
cian.25 Subsequently, the developers of the FACT-General 
questionnaire created FACT-Taxane, a more specific tool to 
assess QoL in patients receiving taxanes.3 FACT-Taxane con-
sists of both FACT-General and an added taxane subscale. The 
subscale has 16 items (Table 1), including an 11-item neuro-
toxicity subscale and five additional taxane-specific questions 
related to the effects of arthralgia, myalgia, and skin changes. 
The tool was found to be reliable and sensitive to changes 
in symptoms over time.3 In a study of patients with NSCLC 
receiving treatment with sb-P/C, the impact on QoL of lung 
cancer symptom improvement because of treatment equaled 
the impact of treatment-related toxicities on total QoL, as 
measured by the FACT-Taxane tool. However, with respect to 
patients’ global rating of QoL by using the single item “I am 
content with the quality of my life right now,” improvements 
in disease-related symptoms outweighed concerns about treat-
ment-related toxicity.3
In the trial of nab-P/C versus sb-P/C described above, 
the taxane subscale of the FACT-Taxane questionnaire was 
selected as a methodical instrument to gauge patient perception 
of how treatment-related symptoms affected QoL.3,21 In addi-
tion to assessing sensory neuropathy during study treatment 
by established grading criteria, the investigators also evaluated 
the degree of sensory neuropathy on a visit-by-visit basis. This 
analysis explores patient- and physician-assessed symptoms 
related to treatment with nab-P/C versus sb-P/C in patients with 
advanced NSCLC who participated in the phase 3 study.
PATIENTS AND METHODS
This international, multicenter, randomized phase 3 
study in patients with advanced NSCLC compared the effi-
cacy and safety of nab-P/C versus sb-P/C.21 Patients in the 
nab-P/C arm received nab-paclitaxel 100 mg/m2 on days 1, 
8, and 15, administered as a 30-minute infusion, followed by 
TABLE 1.  The 16-Item Taxane Subscale of FACT-Taxane 
(Adapted from the Study by Cella et al., 2003)3
Category Statement
Neurotoxicity component I have numbness or tingling in my hands
I have numbness or tingling in my feet
I feel discomfort in my hands
I feel discomfort in my feet
I have joint pain or muscle cramps
I feel weak all over
I have trouble hearing
I get a ringing or buzzing in my ears
I have trouble buttoning buttons
I have trouble feeling the shape of small 
objects when they are in my hand
I have trouble walking
Taxane component I feel bloated
My hands are swollen
My legs or feet are swollen
I have pain in my fingertips
I feel discomfort in my feet
FACT, Functional Assessment of Cancer Therapy.
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carboplatin area under the concentration curve = 6 mg*min/
mL (per Calvert formula)26 given on day 1 every 21 days. 
Patients in the sb-P/C arm received sb-paclitaxel 200 mg/m2, 
infused over 3 hours, plus carboplatin area under the concen-
tration curve = 6 mg*min/mL, both given on day 1 every 21 
days. Patients were randomized 1:1 to nab-P/C or sb-P/C and 
stratified by age (< 70 years versus ≥ 70 years), disease stage 
(IIIB versus IV), sex (male versus female), histology (squa-
mous versus adenocarcinoma versus other), and geographic 
region (Canada/United States versus Russia/Ukraine versus 
Japan versus Australia). Six cycles of therapy were encour-
aged, and treatment beyond six cycles was permissible at the 
investigators’ discretion in the absence of progressive disease 
or unacceptable toxicity.
Eligible adults had histologically or cytologically con-
firmed stage IIIB (with or without pleural effusion) or IV 
NSCLC, measurable by Response Evaluation Criteria In Solid 
Tumors version 1.0,4 an Eastern Cooperative Oncology Group 
PS of 0 to 1, and a life expectancy of more than 12 weeks. 
Patients were previously untreated for metastatic disease and 
received no radiotherapy within 4 weeks of enrollment. Prior 
adjuvant chemotherapy was permitted if it had been com-
pleted 12 months or more before study enrollment. Patients 
were excluded from the study if they had untreated or symp-
tomatic brain metastases.
This study was approved by the independent eth-
ics committees of the participating medical institutions 
and was conducted in compliance with the World Medical 
Association Declaration of Helsinki and Good Clinical 
Practice and Guidelines of the International Conference on 
Harmonization.27 Written informed consent was obtained 
from all patients before study initiation.
Physician-assessed toxicities in this trial were classified 
by both the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) version 3.0 and 
by Medical Dictionary of Regulatory Activities (MedDRA) 
criteria.
Patient-reported symptoms were assessed using the 
16-item taxane subscale of the FACT-Taxane instrument 
(Table 1), which includes a neurotoxicity subscale compris-
ing 11 questions and five more questions on additional tax-
ane-related symptoms, such as myalgia, arthralgia, and skin 
changes.3 All 16 questions from the taxane subscale were 
completed at baseline and on day 1 of each treatment cycle. 
Patients gave each statement a score of 0 (not at all), 1 (a little 
bit), 2 (somewhat), 3 (quite a bit), or 4 (very much). Selected 
questions from the neurotoxicity and taxane components of 
the FACT-Taxane were grouped into predefined subscores for 
peripheral neuropathy, pain, hearing, and edema as defined 
in Table 2. Responses to all questions were analyzed in total, 
individually, and as the following groups: peripheral neuropa-
thy, pain, hearing, and edema.
Descriptive statistics were used to summarize patient-
assessed responses from the FACT-Taxane scale, including 
mean change from baseline at each cycle; differences between 
treatment arms were assessed using the two-sample t test by 
visit or repeated measurement across all visits. In all charts of 
FACT-Taxane data, the values for cycles 2 to 8 and final evalu-
ation are mean changes from the baseline score.
Physicians conducted a detailed analysis of sensory 
neuropathy by evaluating patients at every cycle and coding 
severity over the course of treatment using the five-grade 
NCI CTCAE version 3.0 scale: grade 1—asymptomatic, 
loss of deep tendon reflexes or paresthesia, including tin-
gling but not interfering with function; grade 2—sensory 
alteration or paresthesia, including tingling and interfering 
with function but not interfering with activities of daily liv-
ing; grade 3—sensory alteration or paresthesia interfering 
with activities of daily living; grade 4—disabling; and grade 
5—death.
RESULTS
Of the 1038 patients in the treated population, 1031 
(99%) completed the FACT-Taxane questionnaire at baseline. 
Compliance with the questionnaire through eight cycles was 
also 99% (completed in 4278 of 4335 cycles). Baseline scores 
of all individual items, the total score of all 16 items, and each 
subscore were balanced between the treatment arms. There 
was a significant treatment effect favoring nab-P/C over sb-
P/C over the entire course of treatment for the total score of all 
16 items (Fig. 1; p < 0.001) as well as for the 11-item neuro-
toxicity subscore (p < 0.001).
Figure 2 shows the results of the FACT-Taxane periph-
eral neuropathy subscore through cycle 8 of treatment. 
Figure 2A reflects the composite results of the five peripheral 
neuropathy questions, whereas Figure 2B–F shows the graph 
for each individual question. The composite score and each 
individual question subscore revealed a lesser change over 
the course of treatment for the nab-P/C group versus the sb-
P/C group (p < 0.001 for all comparisons), suggesting less 
development of treatment-related symptoms with nab-P/C. 
Furthermore, the composite score revealed statistically sig-
nificant differences from baseline to each of cycles 2 to 8 
(p ≤ 0.002 for each). These values were consistent with the 
physician assessment of peripheral neuropathy by cycle 
(Fig. 3) and the number of patients who experienced at least 
one peripheral neuropathy adverse event of grade 3 or higher 
by MedDRA criteria (3% versus 12%; p < 0.001).21
TABLE 2.  FACT-Taxane Subscores
Category Statement
Peripheral neuropathy I have numbness or tingling in my hands
I have numbness or tingling in my feet
I have trouble buttoning buttons
I have trouble feeling the shape of small 
objects when they are in my hands
I have pain in my fingertips
Pain I feel discomfort in my hands
I feel discomfort in my feet
Hearing I have trouble hearing
I get ringing or buzzing in my ears
Edema I feel bloated
My hands are swollen
My legs or feet are swollen
FACT, Functional Assessment of Cancer Therapy.
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Of note, deterioration in the patient-reported peripheral 
neuropathy subscore at or after the development of grade 3 or 
higher peripheral neuropathy was substantially less for nab-
P/C versus sb-P/C (median change from baseline 4.5 versus 
10). The median time to improvement to MedDRA grade 1 or 
lower peripheral neuropathy was shorter for nab-P/C versus 
sb-P/C (38 versus 104 days), although this difference was not 
statistically significant (p = 0.326).
The composite scores for pain and the subscores for 
individual questions are shown in Figure 4. The change 
over the course of treatment for the composite score sig-
nificantly favored the nab-P/C arm over the sb-P/C arm 
(p < 0.001). The changes over the course of treatment for each 
individual question also significantly favored nab-P/C versus 
sb-P/C (p < 0.001 for each). In addition, patient-reported dete-
rioration in the pain subscore at or after the onset of grade 3 
or higher peripheral neuropathy was less for nab-P/C versus 
sb-P/C (median change from baseline 1.0 versus 4.0). These 
patient-reported results were consistent with those from an 
earlier report of adverse event grading for grade 3 myalgia 
(< 1% for nab-P/C versus 2% for sb-P/C; p = 0.011) and 
arthralgia (0% for nab-P/C versus 2% for sb-P/C; p = 0.008).21
Figures 5 and 6 show the composite scores for the hear-
ing and edema categories, respectively. The hearing subscore 
over the course of treatment favored nab-P/C versus sb-P/C 
(p = 0.002); however, the edema subscore change over the 
course of treatment did not differ significantly between nab-
P/C and sb-P/C (p = 0.437), suggesting that patient perception 
of edema was similar between the two groups.
DISCUSSION
This is the largest study in NSCLC that evaluated the 
impact of taxane-related toxicity on QoL as reported by patients 
using the taxane subscore module of the FACT-Taxane instru-
ment. The robustness of this analysis is underscored by the more 
than 99% completion rate of this QoL instrument by patients in 
the study at baseline, through treatment, and during follow-up. 
In addition to patients reporting the impact of sensory neuropa-
thy on QoL, physicians graded sensory neuropathy during the 
same office visits. The results of patient and physician reports 
showed a striking similarity. By both FACT-Taxane and phy-
sician assessment, nab-P/C seemed superior to sb-P/C with 
respect to neurotoxic effects. Specifically, patients in the nab-
P/C arm noted less severe peripheral neuropathy, neuropathic 
pain in the hands and feet, and hearing loss. Patient-reported 
edema subscores seemed to be similar between the two treat-
ment groups. Taken together, these findings demonstrated an 
advantage for nab-P/C with respect to patient-reported treat-
ment-related symptoms in this trial of patients being treated 
for advanced NSCLC. Importantly, patient-reported assess-
ment of neuropathy mirrored the physician-evaluated degree 
of neuropathy with respect to both the cumulative change over 
time and visit-by-visit differences between the treatment arms, 
further validating the FACT-Taxane tool.
The patient-reported peripheral neuropathy data in this 
report are consistent with adverse event data collected sepa-
rately and previously reported.21 Notably, the MedDRA assess-
ment of neuropathy revealed that 3% of patients in the nab-P/C 
arm experienced a peripheral neuropathy event of grade 3 or 
higher versus 12% of patients in the sb-P/C arm (p < 0.001). 
Assessments of peripheral neuropathy by using NCI CTCAE 
criteria for nab-P/C and sb-P/C were also 3% and 12%, respec-
tively (p < 0.001).21 In addition, the median time to improve-
ment of peripheral neuropathy from MedDRA grade 3 to grade 
1 or lower was 38 days for nab-P/C versus 104 days for sb-P/C. 
The consistent findings of three different methods for assessing 
peripheral neuropathy (adverse event data, physician assessment 
by cycle of treatment, and FACT-Taxane) confirm that nab-P/C 
resulted in a lower incidence of neuropathy-associated symp-
toms versus sb-P/C. In addition, the changes from baseline in the 
FACT-Taxane peripheral neuropathy and pain subscale scores 
were lower in the nab-P/C arm versus the sb-P/C arm at or after 
the onset of peripheral neuropathy of grade 3 or higher.
The rate and severity of peripheral neuropathy are partly 
dependent on the maximum plasma concentration (C
max
) of the 
taxane administered as well as the schedule of administration 
and taxane used.17,20,28–31 A phase 3 MBC trial reported a higher 
rate of peripheral neuropathy for nab-P 260 mg/m2 versus sb-P 
175 mg/m2, each administered on an every-3-week sched-
ule (q3w; 10% versus 2%; p < 0.001).14 However, the time to 
improvement of grade 3 peripheral neuropathy by 1 grade or 
higher was 22 days for nab-P versus 79 days for sb-P.14,32
A pharmacokinetic study demonstrated that nab-P 
administered at 260 mg/m2 over 30 minutes resulted in an 
approximate fourfold higher C
max
 of total paclitaxel and an 
approximate 10-fold higher C
max
 of unbound paclitaxel com-
pared with sb-P administered at 175 mg/m2 over 3 hours.15 In 
this trial, the infusion time was maintained at 30 minutes but 
the dose was reduced from 260 mg/m2 to 100 mg/m2 for the 
weekly schedule, which would have resulted in a substantially 
reduced C
max
 and, possibly as a consequence, a lower rate of 
peripheral neuropathy in the nab-P/C arm of this trial versus 
the nab-P arm of the phase 3 MBC trial.
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FIGURE 1.  Composite change from baseline for the 16-item 
taxane subscale. Symptoms were reported prior to dos-
ing on day 1 of each cycle. Note that larger bars represent 
greater deteriorations from baseline as perceived by patients. 
BL, baseline; nab-P/C, nab-paclitaxel + carboplatin; sb-P/C, 
solvent-based paclitaxel + carboplatin; SEM, standard error 
of the mean. aP value for treatment effect based on repeated 
measures over treatment period (cycle 2 through end of 
treatment).
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A previous phase 3 trial in advanced NSCLC reported a 
higher rate of grade 2/3 neuropathy in patients who received 
q3w versus weekly sb-P/C (18% versus 12%).22 However, the 
weekly regimen did not demonstrate superior efficacy in that 
trial, and q3w remains the standard schedule for sb-P/C.22,23 
In addition, in the current trial, the cumulative paclitaxel dose 
of nab-P/C was higher than that of sb-P/C (1325 mg/m2 with 
nab-P/C versus 1125 mg/m2 with sb-P/C), as was the median 
paclitaxel dose intensity (82 versus 65 mg/m2/week), suggest-
ing that even though patients were able to receive more pacli-
taxel with nab-P/C, this did not result in more neuropathy.21 
However, the median cumulative carboplatin dose (3140 versus 
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FIGURE 2.  Peripheral neuropathy subscore and individual statements. Symptoms were reported prior to dosing on day 1 of 
each cycle. A, composite peripheral neuropathy subscore, (B) subscore for the statement “I have numbness or tingling in my 
hands,” (C) subscore for the statement “I have numbness or tingling in my feet,” (D) subscore for the statement “I have trouble 
buttoning buttons,” (E) subscore for the statement “I have pain in my fingertips,” and (F) subscore for the statement “I have 
trouble feeling the shape of small objects when they are in my hands.” BL, baseline; nab-P/C, nab-paclitaxel + carboplatin; 
sb-P/C, solvent-based paclitaxel + carboplatin; SEM, standard error of the mean. a = *P value for treatment effect based on 
repeated measures over treatment period (cycle 2 through end of treatment).
88 Copyright © 2013 by the International Association for the Study of Lung Cancer
Hirsh et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014
3315 mg) and median carboplatin dose intensity (166 versus 
204 mg/week) were both lower for nab-P/C versus sb-P/C. The 
exact impact of this marginal difference in carboplatin dose 
on peripheral neuropathy or other components of the FACT-
Taxane questionnaire is difficult to estimate, especially as 
peripheral neuropathy and ototoxicity caused by carboplatin 
(unlike cisplatin) are known to be infrequent.33
Taxane use has been shown to be associated with a triad 
of pain related to sensory neuropathy, myalgia, and arthral-
gia.13,24,34 Results from the pain subscore derived from the 
FACT-Taxane survey in this trial revealed that patients receiv-
ing nab-P/C perceived less pain in the hands and feet com-
pared with patients receiving sb-P/C. The FACT-Taxane tool 
does not directly assess the impact of myalgia and arthralgia 
on patient perception of QoL. We have previously reported 
significantly less grade 3 myalgia (< 1% for nab-P/C versus 
2% for sb-P/C; p = 0.011) and arthralgia (0% for nab-P/C ver-
sus 2% for sb-P/C; p = 0.008) using the adverse event data 
from this study.21 Thus, nab-P/C has a favorable profile in all 
three of these areas of pain, which may be of great importance 
to patients.
One of the more intriguing findings in this study was 
the effect of treatment on patient-reported hearing loss. Few 
reports have indicated taxane-related effects on hearing.35 
The initial publication of this phase 3 trial did not list hearing 
loss as a common physician-assessed adverse event in either 
treatment arm.21 Similarly, the low raw FACT-Taxane hearing 
subscores for both arms of this trial indicated that difficulties 
with hearing were not a major concern. However, the differ-
ence in change from baseline between the nab-P/C and sb-P/C 
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arms was statistically significant (p = 0.002), suggesting that 
patients receiving sb-P/C reported more severe hearing loss 
during treatment versus those receiving nab-P/C. Future study 
would be required to explain this subtle but interesting finding.
Taken together, the data from this analysis revealed a 
robust agreement between patient- and physician-assessed tol-
erability profiles for nab-P/C versus sb-P/C in patients with 
advanced NSCLC. The high rates of compliance with the ques-
tionnaire suggest that these results are indeed representative 
of the trial population. In addition to the favorable results for 
nab-P/C over sb-P/C with respect to treatment-related symp-
toms in this study, some patients may have derived symptom 
relief through the shrinkage of their tumors.2,21 Notably, a 
higher proportion of patients in the nab-P/C arm versus the 
sb-P/C arm achieved an objective response (33% versus 25%; 
p = 0.005).21 Taken together, these data suggest that for patients 
who receive a taxane and a platinum for their first-line treat-
ment of advanced NSCLC, nab-P/C is the preferred choice.
Because the survival time of patients with advanced 
NSCLC is relatively short, patient perception of treatment-
related symptoms becomes especially important.2 Treatment 
for advanced NSCLC is entering an age of personalized medi-
cine dependent on tumor-specific biomarkers.12 However, 
many patients, especially those with squamous tumors, are 
given chemotherapy, often platinum-based doublets, because 
targeted agents are deemed inappropriate or have shown lit-
tle benefit in particular patient populations.36 Because more 
lines of treatment are now available for advanced NSCLC,37 
it is of utmost importance that treatment-related side effects 
are minimized, preserving patients’ QoL and PS, one of the 
most important criteria for receiving treatment.12 Neuropathy, 
myalgia, and arthralgia can severely decrease patients’ PS to 
the point that they can no longer take care of their own needs. 
Thus, nab-P/C represents a regimen for the first-line treatment 
of advanced NSCLC that has a favorable tolerability profile, 
potentially preserving PS and enabling patients in the era of 
personalized medicine to benefit from new agents either in 
combination with this regimen or as a sequential therapy. The 
population of elderly patients with NSCLC is growing, and 
tolerance of progressively more palliative treatments is becom-
ing an important factor in treatment decision making. This is 
particularly relevant in light of the side effects of novel targeted 
agents, including possible drug interactions that cause unfavor-
able toxicities, such as worsening of peripheral neuropathy.
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